NCT01085630 · OUTCOME

Overall Survival

Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy · Source last updated 2021-08-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: 95% Confidence Interval
Time frame: Baseline up to 3 years

What was measured

Overall survival time is defined as the time from randomization to death due to any cause. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator.

Groups in this outcome

Arm A (Observation)

Patients undergo observation until disease progression.

Arm B (Pemetrexed)

Patients receive pemetrexed 500 mg/m2 IV over 10 minutes (or per institutional guidelines) every three weeks. Patients will continue treatment until disease progression or excess toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Arm A (Observation)	22
Arm B (Pemetrexed)	27

Reported measurements

Source class 1

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Arm A (Observation)	11.8	Not reported	9.3	28.7	Not reported
Arm B (Pemetrexed)	16.3	Not reported	10.5	26.0	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
9.3
upper Limit
28.7
value
11.8
group Id
OG001
lower Limit
10.5
upper Limit
26.0
value
16.3

denoms

counts
group Id
OG000
value
22
group Id
OG001
value
27
units
Participants

description

Overall survival time is defined as the time from randomization to death due to any cause. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator.

dispersion Type

95% Confidence Interval

groups

description
Patients undergo observation until disease progression.
id
OG000
title
Arm A (Observation)
description
Patients receive pemetrexed 500 mg/m2 IV over 10 minutes (or per institutional guidelines) every three weeks. Patients will continue treatment until disease progression or excess toxicity.
id
OG001
title
Arm B (Pemetrexed)

param Type

MEDIAN

reporting Status

POSTED

time Frame

Baseline up to 3 years

title

Overall Survival

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice